Conviction in Marinus's (MRNS) Phase 3 RAISE Data Remains High, MRNS is One of Top Picks for 2022, EU Delay Should Not Impact US Timeline - Truist
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $40.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
